Unique mutation in SARS-CoV-2 virus identified from next-generation sequencing
Next-generation sequencing has revealed an 81-base pair mutation of the SARS-CoV-2 virus, which could be used to develop new antivirals or vaccines.
List view / Grid view
Next-generation sequencing has revealed an 81-base pair mutation of the SARS-CoV-2 virus, which could be used to develop new antivirals or vaccines.
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
Bringing together protein science, drug discovery experience and innovative technology, a new collaboration aims to identify novel drug targets for COVID-19.
Engineering antibodies found in a llama, researchers have developed a potential COVID-19 therapy which they say can neutralise SARS-CoV-2.
A novel software made by scientists can be used for the analysis of specific lipid groups and lipid signal molecules which can enable their characterisation with mass spectrometry.
Researchers have unravelled the viral transcriptome and translatome of the herpes simplex virus (HSV-1) to aid disease research and immunotherapy.
Professor Saad Shakir explains why cytokine storms occur in COVID-19 patients and suggests potential therapies for the symptoms of the coronavirus.
Researchers have found that the structure of biocatalysts such as enzymes depends on whether they are in cells or in the test tube.
The antibody targets a cell receptor in blood vessels and slowed breast and lung cancer growth as well as metastasis in murine models.
An international group of researchers has revealed that goblet and ciliated cells in the nose have high levels of the entry proteins for the SARS-CoV-2 coronavirus.
Professor Yehuda Shoenfeld suggests hyperferritinaemia, a condition caused by high ferritin levels, may be causing the severe COVID-19 symptoms.
Induced pluripotent stem cells made to produce insulin and CRISPR, used to correct a genetic defect, cured Wolfram syndrome in mice.
Researchers discovered the monoclonal antibodies of a convalescent Marburg infection patient bound to the glycoprotein and combatted infection in two novel ways.
A new study has revealed that less than 10 percent of respiratory and intestinal cells are susceptible to SARS-CoV-2 infection and expression of ACE2 receptors is driven by the body's immune response.
The developers of a novel method to create immunological assay probes for screening T cells has leveraged their new protocol against COVID-19.